1 November, 2022, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK121, a next-generation small molecule FGFR inhibitor overcoming FGFR resistance mutations, has obtained clinical trial approval from the Food and Drug Administration of the USA (FDA), and will soon launch the Phase I clinical trial for the treatment of patients with advanced solid tumors.

ABSK121 is a small molecule FGFR inhibitor that has been discovered and developed by Abbisko to address both primary FGFR2 and FGFR3 oncogenic alterations and those predicted to drive acquired resistance to current FGFR-targeted therapies, including gatekeeper, molecular brake, and activation loop mutations observed in cholangio, bladder and other cancers. In preclinical studies, ABSK121 demonstrated superior potency and broadest coverage across a wide range of clinically relevant mutations that drive primary disease and acquired resistance.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of  the date on which the statements are made in this article. Except as required by law, we undertake  no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of  unanticipated events. You should read this article completely and with   the understanding that our actual future results or performance may be materially different from  what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of  this article. Any of  these intentions may alter in light of future development.